Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Monoclonal Antibodies For COVID-19: Cocktails Present Efficacy, Manufacturing Tradeoffs

Jul 16 2020

• By Sarah Karlin-Smith

Microbiological bioreactor. Cultivation of microorganisms. Bio-fermentation. Bioengineering. Vaccine production. Creation of medicines. Pharmacology. Laboratory equipment. — Ability to scale manufacturing is a key criteria for Operation Warp Speed therapeutics • Source: Shuttstock

Related Content

Regeneron COVID-19 Therapeutic, Novavax Vaccine Get BARDA Funding To Boost Manufacturing

Jul 08 2020

Hope Is Not A Plan: Manufacturing COVID-19 Therapeutics

Jun 25 2020

Lilly CEO: Monoclonal Antibody Companies Should Share Coronavirus Manufacturing Capacity

Jun 25 2020

Manufacturing Pace Is Key For COVID-19 Vaccine Candidates Hoping To Jump To ‘Warp Speed’

Jun 17 2020

Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection

Jul 07 2020

Related Companies

Regeneron Pharmaceuticals, Inc.

Eli Lilly and Company

Additional Topics

United States Coronavirus COVID-19 Biologics Manufacturing Research & Development Drug Safety Infectious Diseases BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window